Viking Therapeutics has raised about $575m before costs by selling shares and convertible notes, priced the day after it reported that patients on its experimental obesity drug VK2735 kept most of their weight loss on less frequent doses. A filing on 28 September confirmed that both offerings, enlarged by the underwriters' options, closed on 25 September.
The maintenance data
On 22 September Viking reported topline results from the first part of its VK2735 maintenance study, a placebo-controlled trial in about 180 adults with obesity. VK2735 is an injected drug that acts on two gut hormone receptors, GLP-1 and GIP, and is already in Phase 3 trials for obesity.
For the first 21 weeks, participants received weekly injections. People on VK2735 lost about 16% to 19% of their body weight on average depending on dose, against roughly no change on placebo. Across the treated groups, 90% lost at least 10% of their weight and 32% lost at least 20%.
They were then switched for 12 weeks to monthly or every-other-week doses, kept on weekly doses, or moved to placebo. The study measured how much of the week-21 weight loss people still had at week 33.
| Maintenance arm | Share of weight loss kept at week 33 |
|---|---|
| Placebo | 61% |
| Every other week, all doses | 90% |
| Every other week, by dose | 83% to 97% |
| Monthly, all doses | 85% |
| Monthly, by dose | 82% to 90% |
A small group kept on weekly 17.5 mg doses had lost 21.7% of their starting weight by week 33, with no plateau yet. Viking said gastrointestinal side effects during maintenance were not meaningfully different from placebo. One participant in the every-other-week groups and one in the monthly groups stopped treatment because of a side effect.
Louis Aronne, an obesity specialist who is a paid consultant to Viking, said: "Flexibility for patients and providers is paramount for achieving treatment persistence."
The results have limits. They are company-reported topline numbers, the maintenance arms had only about 10 to 16 people each, and the maintenance period lasted 12 weeks. Viking plans a second part of the study to test oral maintenance doses.
Viking Therapeutics: share price, chart and news
The share sale and the convertible notes
September financing
- $316.2m from 9.04m new shares sold at $35.00
- $258.75m of 2.00% convertible notes due 2032
- About $548m combined net proceeds
Morgan Stanley and J.P. Morgan led both deals. The deals were priced on 23 September. Viking sold 7,857,143 shares at $35.00 each, and the underwriters took up their full option on 1,178,571 more on 24 September, for 9,035,714 shares in total and about $297.0m of net proceeds.
The notes started at $225m, and the underwriters also exercised their full $33.75m option. They pay 2.00% a year, every April and October from April 2027, and mature on 15 October 2032. Each $1,000 note converts into 19.7044 shares, a conversion price of about $50.75, roughly 45% above the price of the share sale. Viking can settle conversions in cash, shares or both, and it can redeem the notes from 22 October 2029 if its shares trade above 130% of the conversion price under set conditions. Net proceeds from the notes were about $250.8m.
Viking plans to spend the money on developing and preparing VK2735 for sale, on its amylin-based programme VK3019, and on general research, working capital and corporate costs.
What it means for shareholders
The share sale added about 9.04m shares, and if every note were converted into stock, it would create about 5.1m more. In return, Viking has a much larger cash buffer to fund two late-stage obesity trials, VANQUISH-1 and VANQUISH-2, which test weekly VK2735 injections over 78 weeks.
Viking has no approved product and no sales, and its spending on Phase 3 trials is large. Its drug would also have to compete with weight-loss treatments that are already on the market from much larger companies. The notes add a fixed interest cost and a repayment due in 2032 if they are not converted.
What to watch
- Results from the larger VANQUISH Phase 3 trials
- The second part of the maintenance study, which tests oral maintenance doses
- Progress on oral VK2735 and on VK3019
- How much of the new cash Viking spends each quarter
Sources
- Viking Therapeutics (Form 8-K, Exhibit 99.1): Viking Therapeutics Announces Positive Top-Line Results from VK2735 Maintenance Study (2026-09-22)
- U.S. Securities and Exchange Commission (EDGAR): Viking Therapeutics, Inc. Form 424B5 prospectus supplement: 7,857,143 shares of common stock (2026-09-25)
- U.S. Securities and Exchange Commission (EDGAR): Viking Therapeutics, Inc. Form 8-K: underwriting agreements, common stock offering and 2.00% convertible senior notes due 2032 (2026-09-28)








